Cargando…
Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome
Acute respiratory distress syndrome (ARDS) is a lethal clinical entity that has become an emergency event with the outbreak of COVID-19. However, to date, there are no well-proven pharmacotherapies except dexamethasone. This study is aimed to evaluate IRAK4 inhibitors as a potential treatment for AR...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Authors. Published by Elsevier Masson SAS.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339262/ https://www.ncbi.nlm.nih.gov/pubmed/36076574 http://dx.doi.org/10.1016/j.biopha.2022.113459 |